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Background: There is a well-established association between type 2 diabetes and non-alcoholic fatty liver disease
(NAFLD) secondary to excess accumulation of intrahepatic lipid (IHL), but the mechanistic basis for this association
is unclear. Emerging evidence suggests that in addition to being associated with insulin resistance, NAFLD may be
associated with relative beta-cell dysfunction. We sought to determine the influence of liver fat on hepatic insulin
extraction and indices of beta-cell function in a cohort of apparently healthy older white adults.
Methods: We performed a cross-sectional analysis of 70 healthy participants in the Hertfordshire Physical Activity
Trial (39 males, age 71.3 ± 2.4 years) who underwent oral glucose tolerance testing with glucose, insulin and
C-Peptide levels measured every 30 minutes over two hours. The areas under the concentration curve for glucose,
insulin and C-Peptide were used to quantify hepatic insulin extraction (HIE), the insulinogenic index (IGI), the
C-Peptide increment (CGI), the Disposition Index (DI) and Adaptation Index (AI). Visceral fat was quantified with
magnetic resonance (MR) imaging and IHL with MR spectroscopy. Insulin sensitivity was measured with the Oral
Glucose Insulin Sensitivity (OGIS) model.
Results: 29 of 70 participants (41%) exceeded our arbitrary threshold for NAFLD, i.e. IHL >5.5%. Compared to those
with normal IHL, those with NAFLD had higher weight, BMI, waist and MR visceral fat, with lower insulin sensitivity
and hepatic insulin extraction. Alcohol consumption, age, HbA1c and alanine aminotransferase (ALT) levels were
similar in both groups. Insulin and C-Peptide excursions after oral glucose loading were higher in the NAFLD group,
but the CGI and AI were significantly lower, indicating a relative defect in beta-cell function that is only apparent
when C-Peptide is measured and when dynamic changes in glucose levels and also insulin sensitivity are taken into
account. There was no difference in IGI or DI between the groups.
Conclusions: Although increased IHL was associated with greater insulin secretion, modelled parameters suggested
relative beta-cell dysfunction with NAFLD in apparently healthy older adults, which may be obscured by reduced
hepatic insulin extraction. Further studies quantifying pancreatic fat content directly and its influence on beta cell
function are warranted.
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Excess accumulation of intrahepatic lipid (IHL) leads to
non-alcoholic fatty liver disease (NAFLD), an important
component of the spectrum of metabolic abnormalities
implicated in the pathogenesis of type 2 diabetes melli-
tus [1]. The liver is the primary site of insulin clearance
in humans [2]. Previous studies have suggested that liver
fat accumulation is associated with absolute increases in
insulin secretion from the beta-cell, in order to compen-
sate for insulin resistance and maintain euglycaemia [3].
Beta-cell dysfunction per se is not generally considered
a complication of NAFLD [1,4]. However, several studies
suggest that elevated liver fat is associated with reduced
hepatic insulin extraction (HIE) [5,6]. Thus, it is plaus-
ible that IHL accumulation could be associated with a
relative beta-cell failure to adapt to increasing insulin re-
sistance but that such a defect might not be apparent,
because the concomitant reduction in HIE would lead to
elevated circulating insulin levels. Indeed, the accumula-
tion of ectopic fat in the pancreas is increasingly recog-
nised as a cause of beta-cell dysfunction [7]. While a
study of 64 overweight white adults with a family history
of type 2 diabetes found an association between pancre-
atic fat content and glucose tolerance status, no such as-
sociation was found specifically for measures of beta cell
function [8]. More recently, in a study of almost 1000
Chinese young adults (mean age 21 years), alanine ami-
notransferase (ALT, a marker of hepatic steatosis) was
associated with beta-cell dysfunction. However, a direct
association with liver fat content (measured with com-
puterised tomography) and beta-cell dysfunction was
not found [9].
We sought to determine whether IHL accumulation
was associated with altered indices of beta-cell function,
including those which take account of glucose excursion
and insulin sensitivity in a cohort of healthy older
people. A second objective was to determine the influ-
ence of HIE on the relationship between IHL and those
indices, by comparing insulin-derived beta-cell function
measures with those derived from C-Peptide measures.
For this, we conducted a post-hoc, cross- sectional ana-
lysis of metabolic and anthropometric data from a co-
hort of healthy older adults who participated in the
Hertfordshire Physical Activity Trial (HPAT) [10].
Methods
The rationale and design for the Hertfordshire Physical
Activity Trial (ISRCTN 60986572) have been described
previously [10]. Data reported here relate to post-hoc,
cross-sectional analyses of volunteers’ anthropometric and
metabolic characteristics at the time of their entry into the
study. Each participant provided written informed consent.
The original study protocol was approved by the Hertford-
shire Research Ethics Committee (LREC ref. 05/Q0201/23).Trial participants were recruited from the Hertfordshire
Cohort Study, consisting of men and women born in
Hertfordshire, UK between 1931-39 and still residing
there [11]. Specifically, those who were deemed to be
potentially suitable by their general practitioner for in-
clusion in a supervised aerobic exercise programme and
who lived within ten miles of the exercise facility were
invited to participate, as described previously [10].
Those with known diabetes, untreated or unstable is-
chaemic heart disease or any medical condition that
would preclude participation in an exercise programme
were excluded from the trial. However, participants with
incident diabetes (diagnosed at the time of entry to this
study) were included in these analyses. Recruits attended
the clinical research facility after an overnight fast. Of
106 who attended the screening visit, six were deemed
to be unsuitable for the study because of poor mobility,
pre-existing diabetes, symptoms or signs suggestive of
untreated ischaemic heart disease or a combination of
these factors and were excluded. Of the remaining 100,
MR imaging and spectroscopy was not performed in 30
individuals who had claustrophobia, cardiac pace-
makers or metal implants. Thus, 70 participants who
enrolled in the study had baseline liver spectroscopy
measures performed and constitute the cohort de-
scribed herein.
All measurements were undertaken by trained staff ad-
hering to standard operating procedures. Weight was
measured on a Tanita® (Tokyo, Japan) scale and height
with a Seca® (Hamburg, Germany) wall-mounted stadi-
ometer. Waist circumference was measured using a
D-loop non-stretch fibreglass tape measure and defined
as the midpoint between the lower costal margin and
the level of the superior iliac crests. Magnetic resonance
measures of intrahepatic lipid (IHL) and visceral adipose
tissue (VAT) were conducted on a whole body Siemens
3T Tim® Trio scanner (Erlangen, Germany), as described
previously [10]. A questionnaire was used to quantify
alcohol consumption in units per week.
A standard 75 g oral glucose tolerance test (OGTT)
was performed. Fasting samples were taken for glucose,
insulin and C-peptide levels. Glucose was measured using
a hexokinase assay (Siemens, Frimley, UK). Insulin and
C-Peptide were measured using a fluorometric autoDEL-
FIA immunoassay (Perkin Elmer Life Sciences, Turku,
Finland). After ingestion of glucose, further samples were
taken every 30 minutes over two hours. Samples for glu-
cose and lipid profiles were processed immediately while
those for insulin and C-peptide were spun and frozen for
subsequent batch analysis. All samples were processed in
the same laboratory. The Oral Glucose Insulin Sensitivity
(OGIS) model [12] was used to determine peripheral insu-
lin sensitivity based on dynamic insulin and glucose re-
sponses during the OGTT.
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corporating the individual components of the metabolic
syndrome) by standardising and then summing the fol-
lowing variables: (systolic blood pressure + diastolic
blood pressure)/2, log 2-hour plasma glucose, log fasting
insulin, inverted fasting HDL-cholesterol, log triglyceride
and waist circumference, as previously described [13,14].
The component variables were standardised using sex-
specific means and standard deviations from the larger
Hertfordshire Cohort Study population (n = 3000), from
which these participants were recruited, excluding those
with prevalent diagnosed diabetes.
The areas under the concentration curve (AUC) for
glucose, insulin and C-Peptide during the OGTT were
calculated with the trapezium rule. Hepatic insulin ex-
traction (HIE), a measure of the proportion of insulin
secreted from the pancreas which is removed by the
liver prior to entering the systemic circulation, was de-
rived from the difference in the AUCs for insulin and
C-Peptide using the equation [1 − (AUCinsulin/AUCC −
Peptide)]. The insulinogenic index (IGI), quantifying the
suprabasal insulin increment relative to the correspond-
ing glucose increment within 30 minutes of oral glucose
loading was calculated from [ΔInsulin 30/ΔGlucose 30]
[15,16]. In other words, the IGI provides an estimate of
changes in insulin levels in the context of how glucose
levels are also changing within 30 minutes of glucose in-
gestion. The equivalent index for quantifying the relative
C-Peptide increment (CGI) was calculated using [ΔC −
Peptide 30/ΔGlucose 30]. In order to assess the ability of
beta cells to adapt insulin secretion to changes in insulin
sensitivity, we derived two additional indices, the Dis-
position Index (DI, calculated as the product of IGI and
OGIS) and the Adaptation Index (AI, the product of
CGI and OGIS) [17]. So, in addition to taking changes
in glucose levels into account when considering the rele-
vance of insulin and C-Peptide responses after glucose
ingestion, these latter two indices further take account
of whole body insulin sensitivity.
To study the association between IHL as an exposure
and these various measures of beta-cell function as out-
comes, linear regression was used including IHL as a
continuous exposure and adjusted for age, sex, MRI-
visceral fat area and alcohol consumption. In order to
help to illustrate the differences between those with
normal versus high liver fat content and purely for
presentational purposes, means and standard errors
for each outcome have been described in tables and
figures separately for participants with IHL ≤ 5.5% and
with IHL >5.5%, the latter being the generally ac-
cepted, albeit arbitrarily defined threshold for diagnos-
ing NAFLD [18]. However, in all of our statistical
analyses, IHL was treated as a continuous rather than
a categorical variable.Results
Of the 70 HPAT participants included in these analyses,
39 were men. Three participants (4.3%) were found to
have incident, asymptomatic type 2 diabetes based on
OGTT results and were included in all analyses. A fur-
ther 27 (38.6%) had non-diabetic hyperglycaemia, i.e. ei-
ther impaired fasting glucose, impaired glucose tolerance
or both. The median IHL content was 3.6% (range 0.2-
34.5%) while 42% of participants had IHL >5.5%, thus
exceeding our arbitrary threshold for NAFLD [18]. Data
relating to anthropometric and metabolic characteristics
of the cohort and how these differed between those with
normal versus elevated IHL are summarised in Table 1.
As anticipated, those with NAFLD had increased indices
of adiposity and decreased insulin sensitivity and hepatic
insulin extraction compared to those with normal liver
fat content, with a higher ALT, composite metabolic risk
score and worse lipid profiles. There was no difference
in age, alcohol consumption, smoking status, diabetes
family history, medication usage, blood pressure, total
cholesterol or HbA1c between the groups.
Increased IHL was associated with greater areas under
the curve (AUCs) for glucose, insulin and C-Peptide
during the OGTT, as shown in Figure 1 (A-C). There
was a relatively small but nonetheless statistically signifi-
cant inverse association between IHL and HIE (mean
HIE 88.1 ± 0.5 v 85.6 ± 0.9% in those with normal IHL
and elevated IHL, respectively: adjusted β= -0.2 [-0.3, -0.06],
p < 0.006). Put another way, every 1% rise in IHL was
associated with a 0.2% reduction in HIE. Although there
was an absolute increase in insulin secretion with
higher IHL, there were no significant associations be-
tween IHL and insulin-derived indices of beta-cell func-
tion (insulinogenic index and disposition index – IGI,
DI) as shown in Figure 2 (A and C). However, there
were inverse associations between IHL and C-Peptide
derived measures of beta-cell function (C-Peptide-genic
index and adaptation index – CGI and AI), as shown
in Figure 2 (B and D), such that higher levels of liver
fat accumulation were associated with less beta-cell
C-Peptide secretion. After adjusting for insulin sensitivity
measured by OGIS, the strength of evidence for this asso-
ciation was slightly diminished (beta = -11.5 [-23.7, 0.59],
p = 0.062).
Discussion
These data indicate for the first time that IHL accumula-
tion is associated with impaired beta-cell function in
healthy older individuals. The inverse associations be-
tween liver fat and some, but not all parameters of beta
cell function are of particular interest, because they chal-
lenge the traditional notion that NAFLD is associated
only with impaired insulin action and clearance [1,19].
We found that insulin and C-Peptide secretion after oral
Table 1 Characteristics of study participants with normal liver fat content (IHL ≤ 5.5%) versus those with elevated liver
fat (IHL > 5.5%)
Variable IHL ≤5.5% IHL >5.5% p
Mean ± SD Mean ± SD p
M:F 20:21 - 19:10 -
Age (years) 71.5 2.6 71.0 2.2 0.48
Weight (Kg) 70.1 11.3 84.4 12.7 <0.001
BMI (kg m-2) 25.2 2.7 28.6 3.6 <0.001
Waist (cm) 91.1 10.2 104.6 9.4 <0.001
MRI VAT (cm2) 93.1 48.5 176.5 55.9 <0.001
Alcohol (units/week)* 2.0 (1.0,6.0) 2.0 (0,14.0) 0.88
ALT (iu/l)* 21.0 (17.0,27.0) 32.0 (24.0,36.0) <0.001
HbA1c (%) 5.6 0.3 5.7 0.3 0.20
HIE (%) 88.1 2.8 85.6 4.5 0.01
OGIS (ml min-1 m-2) 438.6 52.1 367.8 52.4 <0.001
IHL (%)* 1.8 (0.9,3.4) 14.6 (7.9,19.0) <0.001
SBP (mmHg) 135.4 18.0 139.2 17.0 0.38
DBP (mmHg) 74.2 8.8 76.0 10.2 0.44
Fasting Glucose (mmol/l) 4.9 0.4 5.2 0.5 0.028
2-hour Glucose (mmol/l) 6.5 1.7 8.2 1.8 <0.001
Fasting Insulin (pmol/l)* 47.0 (32.8,64.6) 77.3 (48.1,102.0) <0.001
Total Cholesterol (mmol/l) 5.8 1.1 5.3 1.2 0.12
HDL-Cholesterol (mmol/l) 1.6 0.4 1.3 0.3 0.007
LDL-Cholesterol (mmol/l) 3.7 0.9 3.3 1.0 0.039
Triglycerides (mmol/l)* 1.0 (0.7,1.3) 1.5 (1.0,2.4) <0.001
zMS -0.40 0.49 0.34 0.44 <0.001
Taking statin (%) 4 (9.8%) 10 (34.5%) 0.011
Taking ACEI/ARB (%) 7 (17.1%) 7 (24.1%) 0.47
Taking Betablocker (%) 5 (12.2%) 7 (24.1%) 0.19
Taking CCB (%) 4 (9.8%) 6 (20.7%) 0.20
Family History of DM (%) 10 (25%) 7 (25.9%) 0.93
Current or ex-smoker (%) 12 (29.3%) 12 (41.4%) 0.29
Continuous variables are summarised as means ± standard deviations, with p-values from t-tests. Continuous variables asterisked (*) have skewed distributions, so
are summarised are medians and interquartile ranges, with p-values from Wilcoxon rank sum tests. Binary variables are summarised as N and %, with p-values
from chi-squared tests.
ACEI – Angiotensin Converting Enzyme Inhibitor; ARB – Angiotensin Receptor Blocker; CCB – Calcium Channel Blocker; DBP – Diastolic Blood Pressure;
DM – Diabetes Mellitus; HDL – High Density Lipoprotein; HIE – Hepatic Insulin Extraction; IHL – Intrahepatic Lipid; LDL – Low Density Lipoprotein; OGIS – oral glucose
insulin sensitivity; SBP – Systolic Blood Pressure; zMS – Standardised Composite Metabolic Risk.
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creased IHL. However, when their secretion was quanti-
fied in the context of dynamic glucose excursions after
oral glucose loading and after further consideration of
peripheral insulin sensitivity, an altogether different
physiological pattern emerged: Increased IHL was asso-
ciated with reduced rather than increased beta-cell
function according to C-Peptide based model parame-
ters (CGI and AI). The absence of any association
with the parameters derived from insulin rather than
C-Peptide may be due to the decreased HIE observedwith increased IHL. This would not influence C-Peptide
levels which are excreted by the kidneys. Our findings
suggest that beta cell dysfunction may be an additional
contributor to dysglycaemia in NAFLD but that re-
duced HIE can mask this phenomenon.
The association between liver fat and reduced HIE is
consistent with previous observations in younger indi-
viduals [5]. However when Mehta et al examined differ-
ences in HIE in men with NAFLD compared to those
with low normal liver fat content (IHL < 1%), there was a









































Figure 1 (A-C): Glucose, insulin and C-Peptide levels during the oral glucose tolerance test. Data are presented as mean ± SE. Dashed lines
represent participants with IHL≤ 5.5%. Solid lines represent participants with IHL > 5.5%, i.e. NAFLD. P values are derived from linear regression
modelling with the exposure IHL treated as a continuous variable and the outcome being the area under the curve for the relevant metabolite,
adjusted for age, gender, alcohol consumption and visceral fat area.
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ing IHL as a continuous rather than a categorical vari-
able in our analyses, we had greater statistical power to
detect a difference in HIE, even though it was a smaller
one (88 v 86%).
The same pathophysiological processes that give rise
to accumulation of ectopic fat within the liver are likely
to account for impaired beta-cell function also [7]. It is
likely that our measures of liver fat reflect ectopic fat de-
position in other non-adipose tissues, including the pan-
creas. Clearly, direct measures of pancreatic fat content
would add strength to our study but were not available.
However, studies that have examined the relationship
between pancreatic fat content and beta-cell dysfunction
have not been entirely conclusive to date. A study of
64 overweight adults with a family history of type 2
diabetes showed that pancreatic fat was associated with
whole body insulin sensitivity and with glucose tol-
erance status, but not with beta-cell function per se [8].
Participants in that study were carefully assessed with
gold-standard measures including hyperinsulinaemic
clamp and the arginine stimulation test, but the relativelyspecific phenotype may have narrowed the metabolic
variability of the cohort and limited statistical power
again. Further studies to determine the influence of
pancreatic fat content on insulin secretion would be
helpful. Additionally, the association between excess fat
accumulation and insulin resistance is known to be me-
diated by inflammatory processes [20], but we did not
measure indices of inflammation here. This is a potentially
important area for future studies to consider.
It was notable that the association between IHL and
CGI no longer achieved an arbitrarily defined threshold
for statistical significance after adjusting for OGIS, when
p = 0.062. However, we do not believe that this negates
our finding that IHL influences beta cell function. AI
and CGI were both convincingly inversely associated
with IHL and while it would have been even more con-
vincing if the association with CGI remained significant
after adjusting for insulin sensitivity, the fact that it
didn’t does not nullify our findings. A key consideration
here is the inverse colinearity between IHL and OGIS,
which is well established. It may be that the observed as-
sociation between IHL and reduced beta cell function is










































Figure 2 (A-D): OGTT-derived indices of beta-cell function. Data are presented as means ± SEM. Dashed bars represent participants with
IHL≤ 5.5%. Solid bars represent participants with IHL > 5.5%, i.e. NAFLD. P values are derived from linear regression modelling with the exposure
IHL treated as a continuous variable, adjusted for age, sex, visceral fat area and alcohol consumption.
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would anticipate that the directions of association with
insulin resistance would be opposite for beta cell func-
tion and liver fat content. Moreover, insulin resistance is
not thought to influence beta cell function per se, it just
leads to more insulin being produced. So, if insulin re-
sistance was directly (as opposed to inversely) associated
with beta cell function, then it might be reasonable to
insist that any assessment of the strength of the associ-
ation between liver fat (which is known to cause insulin
resistance) and beta cell function would need to adjust
for insulin resistance. We don’t believe such an approach
is necessary here, though further studies would clearly
be helpful.
Our study has a number of important strengths. Very
detailed anthropometric and metabolic characterisation
was conducted in each participant. MR spectroscopy is
the most robust non-invasive method for quantifying
IHL. Rather than comparing categories of steatosis, body
fatness or glycaemic status, as many studies do, all our
measures are continuous and represent the distributions
in a relatively healthy cohort of older white participants.
The study also has some limitations, not least that it was
a post-hoc analysis of data from a cohort subgroup who
were willing to participate in an exercise trial. All partic-
ipants in the trial were white. Thus, our results may notbe generalisable to all older people. Also, only 70% of
people who enrolled in the trial had MR imaging at
baseline, while others were unwilling or were too large
for the scanner, which may have introduced bias. Given
the relatively small size of our study population of older
white exercise programme participants, confirmatory
studies in other populations seem warranted.
There was a substantial level of “sub-clinical” meta-
bolic disturbance in this cohort, particularly in relation
to the number of individuals with abnormal glucose me-
tabolism during the OGTT. It is important to note that
these abnormalities were only detected through partici-
pation in the study and were not diagnosed prior to it
(and so were not “prevalent” as such). All of these indi-
viduals volunteered to participate in a twelve-week exer-
cise intervention. Diabetes was one of several exclusion
criteria. Nonetheless, 43% had some form of abnormal
glucose metabolism. None had symptoms of hypergly-
caemia, nor were they on treatment for it at the time of
testing. Within a cohort of this age a certain level of un-
diagnosed metabolic disease, be it diabetes or liver stea-
tosis, is to be expected, so to be able to quantify this so
precisely contributes to the novelty of our findings. We
have kept variation in important but mechanistically less
relevant confounders such as age and ethnicity to a
minimum, while incorporating broader distributions of
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sensitivity and liver fat content.
Conclusion
In our experience, there is a widely held perception that
liver steatosis is associated with increased production of
insulin from the beta-cell in order to compensate for
whole-body insulin resistance. However, the elevation in
insulin levels seen in those with NAFLD is misleading
and is explained by their reduced hepatic insulin extrac-
tion. We have shown for the first time in apparently
healthy older adults that liver steatosis is associated with
a relative defect in beta cell function. We have been
careful to take account of confounding factors such as
age [21], sex [22] and alcohol consumption. Further
studies quantifying pancreatic fat content directly and its
influence on beta cell function would be valuable in elu-
cidating further the mechanistic basis for the develop-
ment of type 2 diabetes.
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